Skip to main content
editorial
. 2018 Mar;10(3):1276–1279. doi: 10.21037/jtd.2018.02.74

Table 1. Ongoing phase III clinical trials of immune checkpoint inhibitors in advanced ESCC.

Agents Treatment Patient population NCT identifier
Nivolumab Nivolumab vs. docetaxel/paclitaxel ESCC or esophageal/GEJ adenocarcinoma in 2nd line setting NCT02569242
Nivolumab + ipilimumab vs.
nivolumab + fluorouracil + cisplatin vs.
fluorouracil + cisplatin		 ESCC in 1st line setting NCT03143153
Pembrolizumab Pembrolizumab vs. docetaxel/paclitaxel/irinotecan ESCC or esophageal/GEJ adenocarcinoma in 2nd line setting NCT02564263

ESCC, esophageal squamous cell carcinoma; GEJ, gastroesophageal junction.